SEK 0.04
(-6.88%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -1772.00 SEK | -312.09% |
2022 | -430.00 SEK | 13.13% |
2021 | -495.00 SEK | -93.36% |
2020 | -256.00 SEK | 34.02% |
2019 | -388.00 SEK | 99.95% |
2018 | -720.23 Thousand SEK | 26.11% |
2017 | -974.73 Thousand SEK | 96.5% |
2016 | -27.88 Million SEK | -25245.72% |
2015 | -110.03 Thousand SEK | 0.0% |
2014 | - SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | -1.73 Million SEK | -97586.23% |
2024 Q2 | -1.31 Million SEK | 100.0% |
2023 FY | -1772.00 SEK | -312.09% |
2023 Q3 | -2032.00 SEK | 21.88% |
2023 Q1 | -2955.00 SEK | -587.21% |
2023 Q2 | -2601.00 SEK | 11.98% |
2023 Q4 | -1772.00 SEK | 12.8% |
2022 Q1 | -663 Thousand SEK | -33.94% |
2022 Q3 | - SEK | 100.0% |
2022 FY | -430.00 SEK | 13.13% |
2022 Q4 | -430.00 SEK | 0.0% |
2022 Q2 | -616 Thousand SEK | 7.09% |
2021 FY | -495.00 SEK | -93.36% |
2021 Q2 | -735 Thousand SEK | 22.06% |
2021 Q4 | -495 Thousand SEK | 6.25% |
2021 Q3 | -528 Thousand SEK | 28.16% |
2021 Q1 | -943 Thousand SEK | -268.36% |
2020 Q3 | - SEK | 0.0% |
2020 FY | -256.00 SEK | 34.02% |
2020 Q1 | - SEK | 0.0% |
2020 Q4 | -256 Thousand SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2019 Q1 | - SEK | 0.0% |
2019 Q4 | - SEK | 0.0% |
2019 FY | -388.00 SEK | 99.95% |
2019 Q3 | - SEK | 0.0% |
2018 FY | -720.23 Thousand SEK | 26.11% |
2018 Q2 | - SEK | 0.0% |
2018 Q4 | - SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 Q1 | - SEK | 0.0% |
2017 FY | -974.73 Thousand SEK | 96.5% |
2017 Q1 | - SEK | 0.0% |
2017 Q4 | - SEK | 0.0% |
2017 Q3 | - SEK | 0.0% |
2017 Q2 | - SEK | 0.0% |
2016 Q4 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2016 FY | -27.88 Million SEK | -25245.72% |
2016 Q3 | - SEK | 0.0% |
2015 Q3 | - SEK | 0.0% |
2015 FY | -110.03 Thousand SEK | 0.0% |
2015 Q2 | - SEK | 0.0% |
2015 Q1 | - SEK | 0.0% |
2015 Q4 | - SEK | 0.0% |
2014 Q4 | - SEK | 0.0% |
2014 FY | - SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AcuCort AB | -1.09 Million SEK | 99.839% |
AlzeCure Pharma AB (publ) | -2508.00 SEK | 29.346% |
BioGaia AB (publ) | 181.2 Million SEK | 100.001% |
Enzymatica AB (publ) | 11.49 Million SEK | 100.015% |
Enorama Pharma AB (publ) | 4.29 Million SEK | 100.041% |
Klaria Pharma Holding AB (publ.) | - SEK | Infinity% |
Moberg Pharma AB (publ) | 7.11 Million SEK | 100.025% |
Nanexa AB (publ) | 1.91 Million SEK | 100.093% |
Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 100.035% |
ODI Pharma AB | - SEK | Infinity% |
Orexo AB (publ) | 42.4 Million SEK | 100.004% |
Probi AB (publ) | 116.7 Million SEK | 100.002% |
Swedencare AB (publ) | 398.1 Million SEK | 100.0% |
Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 100.0% |
Toleranzia AB | -1.34 Million SEK | 99.868% |
Vivesto AB | - SEK | Infinity% |